FrancophonIA/ELRC3.0 huggingface dataset:
English: 9 Leaving the VEYVONDI vial (containing the dissolved product) on your flat work surface, connect the syringe to the clear plastic connector by attaching and turning the syringe clockwise.
Estonian: 9 Jätke lahustatud ravimit sisaldav VEYVONDI viaal tasasele tööpinnale, kinnitage süstal läbipaistva plastist konnektori külge ja pöörake süstalt päripäeva.
English: If your FVIII level is inadequate your doctor may give you a dose of 40-60 IU/kg VEYVONDI 12-24 hours (pre-operative dose) prior to initiating elective surgery in order to raise FVIII levels to the target level (0.4 IU/mL for minor and at least 0.8 IU/mL for major surgery).
Estonian: Kui teie FVIII tase on liiga madal, võib arst teile FVIII sihttasemele (0,4 RÜ/ml kerge ja vähemalt 0,8 RÜ/ml raske operatsiooni korral) tõstmiseks manustada ravimit VEYVONDI annuses 40...60 RÜ/kg 12...24 tundi enne plaanilist operatsiooni (operatsioonieelne annus).
English: Tremor
Estonian: Värisemine
English: NAME OF THE MEDICINAL PRODUCT VEYVONDI 650 IU powder and solvent for solution for injection.
Estonian: RAVIMPREPARAADI NIMETUS VEYVONDI 650 RÜ süstelahuse pulber ja lahusti.
English: Thromboembolic events may occur in case of major overdose.
Estonian: Raske üleannustamise korral võib esineda trombembooliat.
English: What VEYVONDI contains The active substance is vonicog alfa (recombinant human von Willebrand factor).
Estonian: Mida VEYVONDI sisaldab Toimeaine on alfavonikog (rekombinantne inimese von Willebrandi faktor).
English: Discard after three hours.
Estonian: Kolme tunni möödumisel visake ravim ära.
English: Draw the VEYVONDI into the syringe by pulling plunger back slowly.
Estonian: Hoidke süstlakolb kindlasti sissevajutatuna ja tõmmake VEYVONDI süstlasse, tõmmates kolbi aeglaselt tagasi.
English: Sodium citrate Glycine
Estonian: Naatriumtsitraat Glütsiin
English: Sodium citrate, glycine, trehalose dihydrate, mannitol, polysorbate 80 and water for injections.
Estonian: Naatriumtsitraat, glütsiin, trehaloosdihüdraat, mannitool, polüsorbaat 80 ja süstevesi.
English: Replacement levels of VWF:RCo > 0.6 IU/mL (60%) and FVIII:C > 0.4 IU/mL (40%) should be achieved.
Estonian: Saavutada tuleb VWF:RCo asendustase üle 0,6 RÜ/ml (60%) ja FVIII:C asendustase üle 0,4 RÜ/ml (40%).Annustamisjuhised kergete ja raskete hemorraagiate raviks on esitatud tabelis 1.
English: 0.5-0.6 IU/mL 0.4 - 0.5 IU/mL Δ
Estonian: 0,50...0,60 RÜ/ml 0,40...0,50 RÜ/ml Δ
English: Steps
Estonian: Etapid
English: Ensure that the VEYVONDI powder vial and the Sterilised Water for Injections (solvent) are at room temperature prior to preparation.
Estonian: Veenduge, et VEYVONDI pulbriviaal ning steriliseeritud süstevesi (lahusti) oleksid enne kasutamist toatemperatuuril.
English: In patients with inadequate levels of FVIII, a dose of 40-60 IU/kg VEYVONDI should be administered 12-24 hours prior to initiating elective surgery (pre-operative dose), to ensure preoperative endogenous FVIII levels of at least 0.4 IU/mL for minor and at least 0.8 IU/mL for major surgery.
Estonian: Ebapiisava FVIII tasemega patsientidel tuleb endogeense FVIII minimaalse taseme 0,4 RÜ/ml (kerge operatsioon) ja 0,8 RÜ/ml (raske operatsioon) tagamiseks manustada 12...24 tundi enne plaanilise operatsiooni alustamist VEYVONDI annus 40...60 RÜ/kg (operatsioonieelne annus).
English: 9 Leaving the VEYVONDI vial (containing the reconsituted product) on your flat work surface, connect the syringe to the clear plastic connector and turning the syringe clockwise.
Estonian: 9 Jätke manustamiskõlblikuks muudetud ravimit sisaldav VEYVONDI viaal tasasele tööpinnale, ühendage süstal läbipaistva plastist konnektoriga ja pöörake süstalt päripäeva.
English: Excipients: Sodium citrate, glycine, trehalose dihydrate, mannitol, polysorbate 80 and water for injections.
Estonian: Abiained: naatriumtsitraat glütsiin, trehaloosdihüdraat, mannitool, polüsorbaat 80 ja süstevesi.
English: Dosing guidance should be done based on the IR. b Δ = Target peak plasma VWF:RCo - baseline plasma VWF:RCo IR = Incremental Recovery as measured in the subject.
Estonian: b Δ = plasma maksimaalne VWF:RCo sihttase - plasma VWF:RCo algtase IR = täiendav paranemine (Incremental Recovery) mõõdetuna uuritaval.
English: Inhibitors (antibodies) against the VWF may occur in some patients receiving the medicine.These inhibitors, especially at high levels, could cause the treatment to stop working properly.
Estonian: Need inhibiitorid, eriti kui nende tase on kõrge, võivad takistada ravimi õiget toimimist.
English: PHARMACEUTICAL FORM AND CONTENTS Powder and solvent for solution for injection Contents: 1 powder vial, 1 vial with solvent (5 mL), 1 Mix2Vial device
Estonian: Sisu: 1 pulbriviaal, 1 lahustiviaal (5 ml), 1 seade Mix2Vial
English: Additional rFVIII may be required to attain the recommended FVIII:C target peak plasma levels.
Estonian: Soovitatud FVIII:C plasma maksimaalse taseme saavutamiseks võib olla vajalik täiendav rFVIII.
English: There may be a risk of developing blood clots (thrombosis) in case of an accidental high dose.
Estonian: Juhusliku üleannustamise korral võib esineda trombide (tromboosi) tekke oht.
English: Vonicog alfa is a purified recombinant human von Willebrand factor (rVWF).
Estonian: Alfavonikog on puhastatud rekombinantne inimese von Willebrandi faktor (rVWF).
English: PHARMACEUTICAL FORM AND CONTENTS Powder and solvent for solution for injection Contents: 1 powder vial , 1 vial with solvent (10ml), 1 Mix2Vial device
Estonian: Sisu: 1 pulbriviaal, 1 lahustiviaal (10 ml), 1 seade Mix2Vial
English: Table 2 Recommended Target Peak Plasma Levels of VWF:RCo and FVIII:C to be Achieved Prior to Surgery for the Prevention of Excessive Bleeding During and After Surgery
Estonian: Plasma VWF:RCo ja FVIII:C soovituslikud maksimaalsed sihttasemed ülemäärase verejooksu ennetamiseks kirurgilise operatsiooni ajal ja pärast seda
English: PHARMACEUTICAL FORM Powder and solvent for solution for injection.
Estonian: RAVIMVORM JA PAKENDI SUURUS Süstelahuse pulber ja lahusti
English: 0.50 IU/mL
Estonian: 0,50 RÜ/ml
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS SOLVENT VIAL LABEL (10 mL)
Estonian: LAHUSTIVIAALI ETIKETT (10 ml)
English: Do not refrigerate after reconstitution.
Estonian: Ärge pange ravimit pärast manustamiskõlblikuks muutmist külmkappi.
English: 0.40 IU/mL
Estonian: 0,40 RÜ/ml
English: - Ensure that the VEYVONDI powder vial and the sterilised water for injections (solvent) are at room temperature prior to preparation.
Estonian: - Veenduge, et VEYVONDI pulbriviaal ning steriliseeritud süstevesi (lahusti) oleksid enne kasutamist toatemperatuuril.
English: Hot flush
Estonian: Kuumahoog
English: Prevention of bleeding in case of elective surgery
Estonian: - kirurgilise verejooksu ennetamiseks.
English: How to store VEYVONDI
Estonian: Kuidas VEYVONDI't võtta
English: Check with your doctor if you are not sure.
Estonian: Kui te pole selles kindel, pidage nõu oma arstiga.
English: CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Estonian: Juhised ravimi manustamiskõlblikuks muutmiseks ja manustamiseks
English: Haemorrhage
Estonian: Tahhükardia
English: Discard the empty solvent vial.
Estonian: Visake tühi lahustiviaal ära.
English: Dizziness
Estonian: Kerge
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS SOLVENT VIAL LABEL (5mL)
Estonian: LAHUSTIVIAALI ETIKETT (5 ml)
English: 0.60 IU/mL
Estonian: 0,30 RÜ/ml
English: Talk to your doctor before using VEYVONDI.
Estonian: Enne VEYVONDI kasutamist pidage nõu oma arstiga.
English: Instructions for Reconstitution and application
Estonian: Juhised manustamiskõlblikuks muutmiseks
English: OTHER
Estonian: Iga
English: Posology
Estonian: Piltnäide
English: Minimum Duration of treatment
Estonian: RAVIMI VÄLJASTAMISTINGIMUSED
English: Calculation of rVWF dose (to be administered within 1 hour prior to
Estonian: FVIII:C plasma maksimaalne sihttase a rVWF-i annuse arvutamine (manustamiseks 1 tund enne operatsiooni) (vajalik on vWF:RCo RÜ)
English: Tachycardia
Estonian: Pearinglus
English: There is a risk of occurrence of thrombotic events if you have known clinical or laboratory risk factors.Therefore your doctor will monitor you for early signs of thrombosis.
Estonian: Esineb trombootiliste sündmuste tekkerisk, eriti kui teil on teadaolevaid kliinilisi või laboratoorseid tromboosi riskitegureid.
English: Gastrointestinal disorders
Estonian: Süvaveeni tromboos
English: Hypersensitivity
Estonian: Hüpertensioon
English: The vaccine would be given according to official recommendations.
Estonian: Vaktsiin määratakse vastavalt ametlikele soovitustele.
English: Every year, the European Medicines Agency (EMA) will review any new information that may become available and this summary will be updated as necessary.
Estonian: Euroopa Ravimiamet vaatab kõik võimalikud uued andmed igal aastal uuesti läbi ning vajaduse korral uuendab käesolevat kokkuvõtet.
English: It should only be used once a flu pandemic has been officially declared by the World Health Organization or European Union (EU).
Estonian: Seda tohib kasutada ainult Maailma Terviseorganisatsiooni või Euroopa Liidu poolt ametlikult välja kuulutatud gripipandeemia korral.
English: The vaccine contains a flu strain called A/VietNam/1203/2004 (H5N1).
Estonian: See sisaldab gripiviiruse tüve A/VietNam/1203/2004 (H5N1).
English: They can then test this vaccine to see how people react to it, allowing them to predict how people will react when the flu strain causing the pandemic is included.
Estonian: Vaktsiini saab seejärel katsetada, et näha inimeste reaktsiooni sellele, ning see võimaldab prognoosida reageerimist, kui vaktsiin sisaldab pandeemiat põhjustavat gripitüve.
English: If a pandemic has started, however, it may be appropriate to give the vaccine to these patients, as long as facilities for resuscitation are available.
Estonian: Kui pandeemia on juba alanud, võib olla vaja manustada vaktsiini ka neile patsientidele, juhul kui saab kasutada elustamisvõimalusi.
English: The vaccine must not be given to people who have had an anaphylactic reaction (severe allergic reaction) to any of the components of the vaccine, or to any of the substances found at trace (very low) levels in the vaccine, such as formaldehyde, benzonase or sucrose.
Estonian: Vaktsiini ei tohi anda patsientidele, kellel on tekkinud anafülaktiline reaktsioon (raske allergiline reaktsioon) vaktsiini mis tahes komponendi või aine suhtes, mida vaktsiin mikrokogustes sisaldab, näiteks formaldehüüd, bensonaas või sahharoos.
English: It contains influenza (flu) viruses that have been inactivated (killed).
Estonian: See sisaldab inaktiveeritud (hävitatud) gripiviirusi.
English: This vaccine contains a virus called H5N1 that has been inactivated (killed) so that it does not cause any disease.
Estonian: Vaktsiin sisaldab viirust H5N1, mis on inaktiveeritud (hävitatud), et see ei põhjustaks haigust.
English: This means that, because the vaccine is a mock up and does not yet contain the strain of flu virus that is causing a pandemic, it has not been possible to obtain full information about the final pandemic vaccine.
Estonian: See tähendab, et kuna see vaktsiin on imitatsioonvaktsiin ega sisalda veel pandeemiat põhjustava gripiviiruse tüve, ei ole lõpliku pandeemiavaktsiini kohta olnud võimalik hankida ammendavat teavet.
English: The main measure of effectiveness was the production of protective levels of antibodies 21 days after the second vaccination.
Estonian: Efektiivsuse põhinäitaja oli antikehade kaitsva sisalduse tekkimine 21 päeva pärast teist vaktsineerimist.
English: Although levels of antibodies slowly fell over the year after vaccination, a booster dose after 12 months resulted in protective levels of antibodies in 93 to 100% of children who received it.
Estonian: Kuigi üks aasta pärast vaktsineerimist antikehade sisaldus aeglaselt vähenes, tekitas 12 kuu järel tehtud revaktsineerimisannus kaitsva antikehade sisalduse 93-100% lastest.
English: Instead, they can prepare a vaccine that contains a strain of flu virus specifically chosen because nobody has been exposed to it, and to which nobody is immune.
Estonian: Selle asemel saab valmistada vaktsiini, mis sisaldab spetsiaalselt valitud gripiviiruse tüve, millega ei ole keegi kokku puutunud ega ole selle suhtes immuunne.
English: According to criteria laid down by the Committee for Medicinal Products for Human Use (CHMP), a mock-up vaccine needs to bring about protective levels of antibodies in at least 70% of adults for it to be considered suitable.
Estonian: Inimravimite komitee kriteeriumide kohaselt võib imitatsioonvaktsiini pidada sobivaks, kui see tekitab antikehade kaitsva sisalduse vähemalt 70%-l täiskasvanutest.
English: The full EPAR for Pandemic Influenza Vaccine H5N1 Baxter AG can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Pandemic Influenza Vaccine H5N1 Baxter AG kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Before a pandemic starts, nobody knows which strain of flu virus will be involved, so pharmaceutical companies cannot prepare the correct vaccine in advance.
Estonian: Enne pandeemia algust ei ole teada, mis gripiviiruse tüvi selle põhjustab, mille tõttu ei ole võimalik täpselt õiget vaktsiini varem ette valmistada.
English: The second main study involved 305 children aged 9 to 17 years, 306 aged 3 to 8 years and 73 aged 6 to 35 months, and also examined the effect of two 7.5 microgram doses of the vaccine 21 days apart.
Estonian: Teises põhiuuringus osales 305 last vanuses 9-17 eluaastat, 306 last vanuses 3-8 eluaastat ja 73 last vanuses 6-35 kuud; selles uuriti samuti 21-päevase vahega manustatud kahe 7,5-mikrogrammise vaktsiiniannuse mõju.
English: A flu pandemic happens when a new type (strain) of flu virus appears that can spread easily from person to person because people have no immunity (protection) against it. A pandemic can affect most countries and regions around the world.
Estonian: Gripipandeemia tekib, kui ilmub uus gripiviiruse tüvi, mis võib kergesti levida inimeselt inimesele, sest selle vastu puudub immuunsus (kaitse).
English: whole virion influenza virus, propagated in vero cells (continuous cell line of mammalian origin), inactivated, containing antigen of pandemic strain
Estonian: kogu viriooni sisaldav gripivaktsiin, kultiveeritud Vero rakukultuuril (imetajatelt pärinev pidev rakuliin), inaktiveeritud, sisaldab pandeemilise tüve antigeeni
English: The study also looked at the effect of a booster dose given after twelve months in some of the children.
Estonian: Uuringus uuriti mõnel lapsel ka 12 kuu järel manustatud revaktsineerimisannuse mõju.
English: At 21 days after the second injection, 72% of the adults below 60 years of age (192 out of 265) and 74% of those above 60 years of age (200 out of 270) had levels of antibodies that would protect them against H5N1.
Estonian: 21 päeva pärast teist süsti oli 72%-l alla 60-aastastest täiskasvanud patsientidest (192 patsiendil 265st) ja 74%-l üle 60-aastastest patsientidest (200 patsiendil 270st) tekkinud viiruse H5N1 vastu kaitsev antikehade sisaldus.
English: When the company that makes Pandemic Influenza Vaccine H5N1 Baxter AG includes the flu strain responsible for a pandemic in the vaccine, it will collect information on the safety and effectiveness of the final pandemic vaccine, and submit this to the CHMP for evaluation.
Estonian: Kui Pandemic Influenza Vaccine H5N1 Baxter AG tootja lisab vaktsiini pandeemiat põhjustanud gripitüve, kogub ettevõte teavet lõpliku pandeemiavaktsiini ohutuse ja efektiivsuse kohta ning esitab selle hindamiseks inimravimite komiteele.
English: One main study in adults included 561 healthy volunteers, 281 of whom were over the age of 60 years.
Estonian: Ühes Pandemic Influenza Vaccine H5N1 Baxter AG täiskasvanute põhiuuringus osales 561 tervet vabatahtlikku patsienti, kellest 281 olid üle 60-aastased.
English: Similarly in children, after the second 7.5-microgram dose, 85% of children aged 9 to 17 years, 73% of those 3 to 8 years, and 69% of those aged 6 to 35 months had protective levels of antibodies 21 days after the second injection.
Estonian: Samuti oli 85% lastest vanuses 9-17 eluaastat, 73% lastest vanuses 3-8 eluaastat ja 69% lastest vanuses 6-35 kuud tekkinud 21 päeva pärast teist süsti kaitsev antikehade sisaldus.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Pandemic Influenza Vaccine H5N1 Baxter AG on 16 October 2009.
Estonian: Euroopa Komisjon andis Pandemic Influenza Vaccine H5N1 Baxter AG müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 16. oktoobril 2009.
English: This vaccine is the same as the Celvapan H5N1 mock-up vaccine, which was previously authorised in the European Union (EU).
Estonian: See on sama mis Celvapan H5N1-imitatsioonvaktsiin, millel juba on Euroopa Liidus müügiluba.
English: A risk management plan has been developed to ensure that Pandemic Influenza Vaccine H5N1 Baxter AG is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Pandemic Influenza Vaccine H5N1 Baxter AG võimalikult ohutu kasutamine.
English: The company that made the Celvapan H5N1 mock-up vaccine has agreed that its scientific data can be used for Pandemic Influenza Vaccine H5N1 Baxter AG (‘informed consent').
Estonian: Celvapan H5N1-imitatsioonvaktsiini tootja on andnud nõusoleku, et tema teaduslikke andmeid võib kasutada ka Pandemic Influenza Vaccine H5N1 Baxter AG toetuseks.
English: The study looked at the ability of two 7.5 microgram doses of the vaccine, given 21 days apart, to trigger the production of antibodies (‘immunogenicity').The main measures of effectiveness were the levels of antibodies against the flu virus in the blood before vaccination, on the day of the second injection (day 21), and 21 days after the second vaccination (day 42).
Estonian: Efektiivsuse põhinäitaja oli gripiviirusevastaste antikehade sisaldus patsiendi veres enne vaktsineerimist, teise süsti päeval (21. päeval) ja 21 päeva hiljem (42. päeval).
English: For more information about treatment with Pandemic Influenza Vaccine H5N1 Baxter AG, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Pandemic Influenza Vaccine H5N1 Baxter AG kasutamise kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The study showed that Pandemic Influenza Vaccine H5N1 Baxter AG produced an antibody response that met these criteria.
Estonian: Uuring näitas, et Pandemic Influenza Vaccine H5N1 Baxter AG põhjustas sellele kriteeriumile vastava antikehade tekke.
English: The most common side effects with Pandemic Influenza Vaccine H5N1 Baxter AG in adults (seen in more than 1 person in 10) are headache, fatigue (tiredness) and pain at the site of the injection.
Estonian: Pandemic Influenza Vaccine H5N1 Baxter AG kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on peavalu, väsimus ja süstekoha valulikkus.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pandemic Influenza Vaccine H5N1 Baxter AG, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Pandemic Influenza Vaccine H5N1 Baxter AG ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: What measures are being taken to ensure the safe and effective use of Pandemic Influenza Vaccine H5N1 Baxter AG?
Estonian: Mis meetmed võetakse, et tagada Pandemic Influenza Vaccine H5N1 Baxter AG ohutus ja efektiivne kasutamine?
English: The viruses used in Pandemic Influenza Vaccine H5N1 Baxter AG are grown in mammal cells (‘vero cells'), unlike those in some other flu vaccines, which are grown in hen's eggs.
Estonian: Vaktsiinis Pandemic Influenza Vaccine H5N1 Baxter AG kasutatavaid viirusi kasvatatakse imetajarakkudes, teisiti kui mõne teiste gripivaktsiinide viirusi, mida kasvatatakse kanamunades.
English: Pandemic Influenza Vaccine H5N1 Baxter AG is given by injection into the shoulder muscle or thigh in two doses, at least three weeks apart.
Estonian: Vaktsiini Pandemic Influenza Vaccine H5N1 Baxter AG süstitakse deltalihasesse (õlalihasesse) või reielihasesse kahe annusena, mille vahele tuleb jätta vähemalt kolm nädalat.
English: The CHMP decided that Pandemic Influenza Vaccine H5N1 Baxter AG's benefits are greater than its risks in all age groups investigated and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et vaktsiini Pandemic Influenza Vaccine H5N1 Baxter AG kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
English: Pandemic Influenza Vaccine H5N1 Baxter AG is a vaccine to prevent ‘pandemic' flu.
Estonian: Pandemic Influenza Vaccine H5N1 Baxter AG on vaktsiin, mida kasutatakse gripipandeemia ennetamiseks.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pandemic Influenza Vaccine H5N1 Baxter AG.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas vaktsiini Pandemic Influenza Vaccine H5N1 Baxter AG ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas vaktsiini kasutada.
English: Other information about Pandemic Influenza Vaccine H5N1 Baxter AG
Estonian: Muu teave Pandemic Influenza Vaccine H5N1 Baxter AG kohta
English: This is a summary of the European public assessment report (EPAR) for Pandemic Influenza Vaccine H5N1 Baxter AG.
Estonian: See on vaktsiini Pandemic Influenza Vaccine H5N1 Baxter AG avaliku hindamisaruande kokkuvõte.
English: For the full list of all side effects reported with Pandemic Influenza Vaccine H5N1 Baxter AG, see the package leaflet.
Estonian: Pandemic Influenza Vaccine H5N1 Baxter AG kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What information is still awaited for Pandemic Influenza Vaccine H5N1 Baxter AG?
Estonian: Mis teavet Pandemic Influenza Vaccine H5N1 Baxter AG kohta veel oodatakse?
English: Pandemic Influenza Vaccine H5N1 Baxter AG is a ‘mock-up' vaccine.
Estonian: Pandemic Influenza Vaccine H5N1 Baxter AG on süstitav vaktsiin.
English: Why has Pandemic Influenza Vaccine H5N1 Baxter AG been approved?
Estonian: Miks Pandemic Influenza Vaccine H5N1 Baxter AG heaks kiideti?
English: What is Pandemic Influenza Vaccine H5N1 Baxter AG?
Estonian: Mis on Pandemic Influenza Vaccine H5N1 Baxter AG?
English: How does Pandemic Influenza Vaccine H5N1 Baxter AG work?
Estonian: Kuidas Pandemic Influenza Vaccine H5N1 Baxter AG toimib?
English: What is the risk associated with Pandemic Influenza Vaccine H5N1 Baxter AG?
Estonian: Mis riskid Pandemic Influenza Vaccine H5N1 Baxter AG-ga kaasnevad?
English: How has Pandemic Influenza Vaccine H5N1 Baxter AG been studied?
Estonian: Kuidas Pandemic Influenza Vaccine H5N1 Baxter AG-d uuriti?
English: Pandemic Influenza Vaccine H5N1 Baxter AG has been authorised under ‘Exceptional Circumstances'.
Estonian: Pandemic Influenza Vaccine H5N1 Baxter AG-le on antud müügiluba erandkorras.
English: How is Pandemic Influenza Vaccine H5N1 Baxter AG used?
Estonian: Kuidas Pandemic Influenza Vaccine H5N1 Baxter AG-d kasutatakse?
English: What is Pandemic Influenza Vaccine H5N1 Baxter AG used for?
Estonian: Milleks Pandemic Influenza Vaccine H5N1 Baxter AG-d kasutatakse?
English: Date of first authorisation: 18.08.2011 Date of last renewal: 21.06.2016
Estonian: Esmase müügilao väljastamise kuupäev: 18.08.2011 Müügiloa viimase uuendamise kuupäev: 21.06.2016
English: Do not breach the vial more than 50 times.
Estonian: Viaali ei tohi avada üle 50 korra.
English: 15 days;
Estonian: 15 päeva;